<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916210</url>
  </required_header>
  <id_info>
    <org_study_id>2020P001099</org_study_id>
    <secondary_id>U19NS115388</secondary_id>
    <nct_id>NCT04916210</nct_id>
  </id_info>
  <brief_title>Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY</brief_title>
  <acronym>DISCOVERY</acronym>
  <official_title>Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of the DISCOVERY study is to better understand what factors contribute to&#xD;
      changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a&#xD;
      stroke. The purpose of the study is to help doctors identify patients at risk for dementia&#xD;
      (decline in memory, thinking and other mental abilities that significantly affects daily&#xD;
      functioning) after their stroke so that future treatments may be developed to improve&#xD;
      outcomes in stroke patients. For this study, a &quot;stroke&quot; is defined as either (1) an acute&#xD;
      ischemic stroke (AIS, or blood clot in the brain), (2) an intracerebral hemorrhage (ICH, or&#xD;
      bleeding in the brain), (3) or an aneurysmal subarachnoid hemorrhage (aSAH, or bleeding&#xD;
      around the brain caused by an abnormal bulge in a blood vessel that bursts).&#xD;
&#xD;
      The investigators hypothesize that:&#xD;
&#xD;
        1. The size, type and location of the stroke play an important role in recovery of thinking&#xD;
           and memory abilities after stroke, and pre-existing indicators of brain health further&#xD;
           determine the extent of this recovery.&#xD;
&#xD;
        2. Specific stroke events occurring in individuals with underlying genetic or biological&#xD;
           risk factors can cause further declines in brain heath, leading to changes in thinking&#xD;
           and memory abilities after stroke.&#xD;
&#xD;
        3. Studying thinking and memory alongside brain imaging and blood samples in patients who&#xD;
           have had a stroke allows for earlier identification of declining brain health and&#xD;
           development of individualized treatment plans to improve patient outcomes in the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, observational, nested-cohort study. A total of 8,000&#xD;
      patients hospitalized at the DISCOVERY clinical sites with acute-onset AIS, ICH or aSAH and&#xD;
      no history of dementia will be enrolled.&#xD;
&#xD;
      All participants will undergo baseline screening for evidence of pre-stroke dementia. Those&#xD;
      who pass baseline screening will complete a blood draw and a series of cognitive and&#xD;
      functional assessments at baseline.&#xD;
&#xD;
      Participants will undergo in-person (3-6 months, 18 months) and telephone (annual) follow-up&#xD;
      visits for the duration of the study to assess for longitudinal cognitive and functional&#xD;
      outcomes. In addition to Tier 1 procedures, at each in-person follow-up visit, Tier 2&#xD;
      participants will also undergo brain MRI scanning, comprehensive cognitive assessment&#xD;
      batteries and longitudinal blood collection; and Tier 3 participants will also complete a&#xD;
      specialized imaging of the brain (amyloid- and tau-PET/CT scans), which is intended to&#xD;
      identify special biomarkers of dementia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in post-stroke cognitive impairment and dementia (PSCID) diagnosis status</measure>
    <time_frame>Baseline to 48 months post-index stroke</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive function</measure>
    <time_frame>Baseline to 3-6, 12, 18, 24, 36 and 48 months post-index stroke</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Subarachnoid Hemorrhage</condition>
  <condition>Dementia, Vascular</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Vascular Cognitive Impairment</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A blood sample will be collected from all participants at baseline for genomic and&#xD;
      blood-based biomarker analyses. Tier 2 and 3 participants will undergo additional blood draws&#xD;
      at each in-person follow-up visit for the collection of whole blood and RNA for longitudinal&#xD;
      blood-based biomarker and DNA methylation (DNAm) analyses.&#xD;
&#xD;
      Plasma, whole blood and RNA samples will be frozen and stored at the DISCOVERY Biorepository&#xD;
      at the University of California, San Diego (UCSD) for further processing, storage and&#xD;
      analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with recent (≤ 6 weeks) acute ischemic stroke, intracerebral hemorrhage or&#xD;
        aneurysmal subarachnoid hemorrhage and no history of dementia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years&#xD;
&#xD;
          2. Admitted to the hospital with a diagnosis of acute ischemic stroke (AIS),&#xD;
             intracerebral hemorrhage (ICH), or aneurysmal subarachnoid hemorrhage (aSAH)&#xD;
&#xD;
          3. Radiographic confirmatory evidence of: (1) AIS (based on a focal area of restricted&#xD;
             diffusion on MRI), (2) non-traumatic ICH (based on evidence of acute parenchymal&#xD;
             hemorrhage CT or brain MRI) or (3) non-traumatic acute aSAH (based on evidence of&#xD;
             subarachnoid hemorrhage on CT or MRI and evidence of aneurysm on CT angiography, MR&#xD;
             angiography, or conventional catheter-based angiography)&#xD;
&#xD;
          4. Able to complete baseline visit in person or by phone within 6 weeks of stroke onset&#xD;
&#xD;
          5. Able to provide informed consent by self or proxy&#xD;
&#xD;
          6. Fluent in English or Spanish prior to stroke onset&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Documented history of pre-stroke dementia or fails dementia pre-screen&#xD;
&#xD;
          2. Concurrently enrolled into a study that is not approved under the DISCOVERY&#xD;
             Co-Enrollment Policy&#xD;
&#xD;
          3. Unable to complete study protocol (advanced directives such as comfort measures only,&#xD;
             or inability to complete the study due to severe medical/behavioral co-morbidities),&#xD;
             as determined by physician investigator during screening process&#xD;
&#xD;
             Additional exclusion criteria for Tier 2 participants:&#xD;
&#xD;
          4. Contraindication to MRI: presence of electrically, magnetically, or mechanically&#xD;
             activated implants (such as cardiac pacemakers, cochlear implants, implanted pumps);&#xD;
             or metallic clips in the brain&#xD;
&#xD;
             Additional exclusion criteria for Tier 3 participants:&#xD;
&#xD;
          5. Age &lt;50 years&#xD;
&#xD;
          6. Women who are pregnant or seeking to become pregnant&#xD;
&#xD;
          7. Known to have one of the following genetic conditions which can increase the risk of&#xD;
             developing cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia,&#xD;
             Wiskott-Aldrich syndrome, Down's syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalia Rost, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Greenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James Meschia, MD</last_name>
    <phone>904-953-6515</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Orjuela, MD, MS</last_name>
    </contact>
    <investigator>
      <last_name>Karen Orjuela, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Lin, MD, MPH</last_name>
    </contact>
    <investigator>
      <last_name>Michelle Lin, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisheva Coleman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elisheva Coleman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Leira, MD, MS</last_name>
    </contact>
    <investigator>
      <last_name>Enrique Leira, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prachi Mehndiratta, MBBS</last_name>
    </contact>
    <contact_backup>
      <last_name>Gunjan Parikh, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Prachi Mehndiratta, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gunjan Parikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Etherton, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Mark Etherton, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Bushnell, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cheryl Bushnell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://discoverystudy.org/</url>
    <description>Official Website for the DISCOVERY Study</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Natalia Rost, MD</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Contingent upon approval from the DISCOVERY Project Steering Committee and Sharing Subcommittee, or the NINDS (upon completion of the study), data, imaging and/or samples from consenting participants may be shared with other external researchers for future research. All identifiers and study-specific codes will be removed and assigned a second randomized identifier. The key linking each identifier to a study-specific code will be in the possession of the DISCOVERY Repository Core and will not be shared with external researchers.&#xD;
Upon completion of the study, the study database will be available to NINDS along with a data dictionary and all information needed to utilize the data in future research in accordance with the informed consent. De-identified genetic information derived from this study will be deposited in the US NIH genomic database (dbGAP and future iterations) and used for future research.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

